According to DelveInsight's analysis, the market for GIST is anticipated to increase during the forecast period (2025–2034), owing to the launch of e ...

Growth Drivers include demand for protein-based drugs, rise in chronic disease prevalence, precision medicine expansion, biotech advancements, and AI-driven design tools.Dublin, April 14, 2025 (GLOBE ...

GSK plc (LSE/NYSE: GSK) today announced the recipients of its COiMMUNITY Initiative grant program, awarding nearly $2 million to 15 regional, state and national non-profits and community-based groups ...

NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential ...

The IQVIA Institute for Human Data Science has released, Global Trends in R&D 2025 report, Progress in Recapturing Momentum ...

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the ...

Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In GSK To Contact Him Directly To Discuss Their Options ...

Pharma firm GSK has been accused of burying a report said to prove a link between its medication Zantac and cancer, a new ...

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware federal court. The deal blocks the parties from renewing their claims or ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

("GSK" or the "Company") (NYSE: GSK) American Depositary Receipts ("ADRs") between February 5, 2020, and August 14 ... the Deutsche Bank report stated that the total liability could be between $5 ...

Below is Validea's guru fundamental report for GSK PLC (ADR) (GSK). Of the 22 guru strategies we follow, GSK rates highest using our Acquirer's Multiple Investor model based on the published ...